Page last updated: 2024-12-08

3,4-Dichlorobenzenesulfonamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID233097
CHEMBL ID366729
CHEBI ID194766
SCHEMBL ID793608

Synonyms (33)

Synonym
nsc31188
nsc-31188
23815-28-3
IDI1_032646
MAYBRIDGE4_002768
HMS1528N18
AKOS000147476
F1084-0743
3,4-dichloro-benzenesulfonamide
CHEMBL366729 ,
CHEBI:194766
3,4-dichlorobenzenesulonamide
3,4-dichlorobenzenesulfonamide
A816922
bdbm50423785
SCHEMBL793608
3,4-dichlorobenzene-1-sulfonamide
DTXSID20283393
benzenesulfonamide, 3,4-dichloro-
Z45415573
J-015225
BBL103198
STL557008
GS1031
ILLSOONBCBUBOD-UHFFFAOYSA-N
mfcd01314052
MS-20577
4,5-dichlorobenzenesulfonamide
M9RH83L2KL ,
YAA81528
SB80376
unii-m9rh83l2kl
EN300-77795
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carbonic anhydrase 2Bos taurus (cattle)Ki0.15230.00251.13257.5858AID550080
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Processvia Protein(s)Taxonomy
angiotensin-activated signaling pathwayCarbonic anhydrase 2Bos taurus (cattle)
regulation of monoatomic anion transportCarbonic anhydrase 2Bos taurus (cattle)
regulation of intracellular pHCarbonic anhydrase 2Bos taurus (cattle)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
zinc ion bindingCarbonic anhydrase 2Bos taurus (cattle)
cyanamide hydratase activityCarbonic anhydrase 2Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
cytoplasmCarbonic anhydrase 2Bos taurus (cattle)
plasma membraneCarbonic anhydrase 2Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID239922Inhibitory activity against carbonic anhydrase2004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
Topological modeling of lipophilicity, diuretic activity, and carbonic inhibition activity of benzene sulfonamides: a molecular connectivity approach.
AID550080Binding affinity to bovine carbonic anhydrase 22011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
Correlation analyses on binding affinity of substituted benzenesulfonamides with carbonic anhydrase using ab initio MO calculations on their complex structures (II).
AID50169Inhibitory activity against bovine Carbonic anhydrase1989Journal of medicinal chemistry, May, Volume: 32, Issue:5
The binding of benzenesulfonamides to carbonic anhydrase enzyme. A molecular mechanics study and quantitative structure-activity relationships.
AID1136505Inhibition of carbonic anhydrase (unknown origin)1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
A manual method for applying the Hansch approach to drug design.
AID237572Diuretic activity was determined2004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
Topological modeling of lipophilicity, diuretic activity, and carbonic inhibition activity of benzene sulfonamides: a molecular connectivity approach.
AID237031Partition coefficient (logP)2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Novel use of chemical shift in NMR as molecular descriptor: a first report on modeling carbonic anhydrase inhibitory activity and related parameters.
AID244692Diuretic activity was determined2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Novel use of chemical shift in NMR as molecular descriptor: a first report on modeling carbonic anhydrase inhibitory activity and related parameters.
AID237422Partition coefficient (logP)2004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
Topological modeling of lipophilicity, diuretic activity, and carbonic inhibition activity of benzene sulfonamides: a molecular connectivity approach.
AID239935Inhibition constant against carbonic anhydrase2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Novel use of chemical shift in NMR as molecular descriptor: a first report on modeling carbonic anhydrase inhibitory activity and related parameters.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (25.00)18.7374
1990's0 (0.00)18.2507
2000's2 (25.00)29.6817
2010's4 (50.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.13 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]